U-CHAMP: Urban Cardiovascular Health Assessment and Management Program

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by University of Calgary.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
University of Alberta
Information provided by:
University of Calgary
ClinicalTrials.gov Identifier:
NCT00626041
First received: January 14, 2008
Last updated: January 25, 2010
Last verified: January 2010
  Purpose

High blood pressure, elevated blood glucose and high cholesterol are related to the increased risk of stroke and heart disease. Many studies have shown that this risk can be significantly reduced by lowering blood pressure, blood glucose and cholesterol levels.

Through a collaborative effort between Calgary Safeway pharmacists and Calgary Health Region family physician PCN's, U-CHAMP will deliver a program to assist in the identification and management of people with elevated blood pressure, blood glucose and cholesterol and through this effort, reduce the risk of heart disease and stroke in the urban Calgary population aged 18-85 years.


Condition Intervention
Cardiovascular Diseases
Hypertension
Hyperlipidemia
Hyperglycemia
Other: participant referral to primary care network physician

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: U-CHAMP: Urban Cardiovascular Health Assessment and Management Program

Resource links provided by NLM:


Further study details as provided by University of Calgary:

Primary Outcome Measures:
  • Change in systolic blood pressure between baseline (average of visits one and two) and program end (final visit). [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of screened participants identified as being above blood pressure, cholesterol and blood glucose targets at visit two [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Proportion of participants that achieve published blood pressure (lipid and diabetes when appropriate) targets by program end [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Proportion of individuals that obtain both a baseline and end of program full lipid panel [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Change in Framingham Global Cardiovascular Risk score (in those participants that do not have known vascular disease or diabetes and have a recorded baseline and end-of-study full lipid panel). [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Proportion of individuals that have changes in drug therapy (new medication and/or dosage increase). [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 110
Study Start Date: February 2008
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
referral to primary care network for management of blood pressure, lipids and diabetes.
Other: participant referral to primary care network physician
blood pressure, cholesterol and hemoglobin A1c screening and management

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults 18-85 years
  • Signed consent

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00626041

Contacts
Contact: Donna M. Galvin, BScPharm 403 938-1589 dgalvin@ucalgary.ca

Locations
Canada, Alberta
Calgary Safeway Pharmacy - Crowfoot Location Recruiting
Calgary, Alberta, Canada, T3G 2L4
Contact: Rita Bowron, BScPharm    403-831-6987      
Principal Investigator: Charlotte A Jones, PhD MD         
Coop Pharmacy - Crowfoot Location Terminated
Calgary, Alberta, Canada, T3G 2L5
Sponsors and Collaborators
University of Calgary
University of Alberta
Investigators
Principal Investigator: Charlotte Jones, PhD, MD University of Calgary
  More Information

Additional Information:
Publications:
McLean DL, McAlister FA, Johnson JA, King KM, Jones CA, Tsuyuki RT. SCRIP-Hypertension program - Improving blood pressure management in patients with diabetes: The design of the SCRIP-HTN study. Canadian Pharmaceutical Journal 139: 1-4, 2006.
British Cardiac Society, British Hypertenion Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (5): 2005

Responsible Party: Dr. Charlotte Jones, University of Calgary
ClinicalTrials.gov Identifier: NCT00626041     History of Changes
Other Study ID Numbers: 03 71550000144
Study First Received: January 14, 2008
Last Updated: January 25, 2010
Health Authority: Canada: Health Canada

Keywords provided by University of Calgary:
Community pharmacies
Primary care networks
Global risk assessment
Blood pressure screening

Additional relevant MeSH terms:
Cardiovascular Diseases
Hyperglycemia
Hyperlipidemias
Hypertension
Glucose Metabolism Disorders
Metabolic Diseases
Dyslipidemias
Lipid Metabolism Disorders
Vascular Diseases

ClinicalTrials.gov processed this record on August 28, 2014